Exploring Long Noncoding RNA AC010536.1: A New Frontier in Colon Cancer Diagnosis and Prognosis

Abstract

Background: The long non-coding RNA (lncRNA) AC010536.1 is abnormally expressed in multiple cancer types, suggesting it may function as an oncogene. Despite this, its role in colon cancer has not been extensively investigated. This study aimed to assess the diagnostic and prognostic value of AC010536.1 in colon cancer. Methods: The cancer genome atlas database (TCGA) was utilized to examine the clinical significance of AC010536.1 in colon cancer. Survival analysis was performed using the Kaplan–Meier and Cox regression analyses. Nomograms were constructed to predict patient survival. The association between AC010536.1 expression patterns and immune cell features was investigated using the CIBERSORT method (Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts). Results: The abnormal high expression of AC010536.1 was observed in 12 types of malignancies, including colon cancer. Survival analysis revealed that higher levels of AC010536.1 were linked to poorer clinical outcomes. Multivariable Cox analysis confirmed that AC010536.1 was an independent prognostic indicator for colon cancer. The receiver operating curve (ROC) analysis demonstrated a strong diagnostic capacity of AC010536.1, and the area under the curve (AUC) is 0.829. Furthermore, the study investigated the relationship between AC010536.1 expression, tumor-infiltrating immune cells and the effectiveness of chemotherapeutic agents. Conclusions: Our findings demonstrated that AC010536.1 was overexpressed in colon cancer and could be used to predict survival of patient with colon cancer. Moreover, the data also indicated that the expression of AC010536.1 could predict the efficacy of specific anti-tumor drugs.